-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Incannex Healthcare Limited (NASDAQ:IXHL) Short Interest Update
Incannex Healthcare Limited (NASDAQ:IXHL) Short Interest Update
Incannex Healthcare Limited (NASDAQ:IXHL – Get Rating) was the target of a significant decrease in short interest in the month of January. As of January 15th, there was short interest totalling 11,000 shares, a decrease of 24.7% from the December 31st total of 14,600 shares. Based on an average trading volume of 6,800 shares, the days-to-cover ratio is currently 1.6 days.
Incannex Healthcare Stock Down 0.9 %
Incannex Healthcare stock opened at $3.41 on Monday. Incannex Healthcare has a twelve month low of $2.60 and a twelve month high of $90.00. The stock's fifty day simple moving average is $3.34 and its 200-day simple moving average is $3.98.
Get Incannex Healthcare alerts:Institutional Trading of Incannex Healthcare
Large investors have recently modified their holdings of the stock. Jane Street Group LLC acquired a new position in shares of Incannex Healthcare during the first quarter worth $378,000. FNY Investment Advisers LLC acquired a new position in shares of Incannex Healthcare during the third quarter worth $69,000. Finally, UBS Group AG acquired a new position in shares of Incannex Healthcare during the first quarter worth $25,000. Hedge funds and other institutional investors own 0.07% of the company's stock.
About Incannex Healthcare
(Get Rating)Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies in Australia. It offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. The company also develops IHL-42X, which has completed Phase IIa clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis.
Featured Articles
- Get a free copy of the StockNews.com research report on Incannex Healthcare (IXHL)
- Is Seagate Technology Signaling the End of its Normalization?
- eHealth Stock Rises from the Ashes. Time to Get In?
- Can Yext A.I. Search Platform Drive Growth in 2023?
- Cassava Sciences Stock Undervalued with Its $124 Price Target?
- Constellation Brands: Are Consumers Trading Down for Rail Drinks?
Receive News & Ratings for Incannex Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incannex Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
Incannex Healthcare Limited (NASDAQ:IXHL – Get Rating) was the target of a significant decrease in short interest in the month of January. As of January 15th, there was short interest totalling 11,000 shares, a decrease of 24.7% from the December 31st total of 14,600 shares. Based on an average trading volume of 6,800 shares, the days-to-cover ratio is currently 1.6 days.
盈康醫療保健有限公司 (NASDAQ: IXHL — 獲得評級) 是一月份短期利率大幅下降的目標。截至 1 月 15 日,短期利息總額為 11,000 股,較十二月三十一日共 14,600 股股份減少 24.7%。根據 6,800 股的平均交易量,目前的日數比率為 1.6 天。
Incannex Healthcare Stock Down 0.9 %
永康醫療股票下跌 0.9%
Incannex Healthcare stock opened at $3.41 on Monday. Incannex Healthcare has a twelve month low of $2.60 and a twelve month high of $90.00. The stock's fifty day simple moving average is $3.34 and its 200-day simple moving average is $3.98.
富康強醫療保健股票週一以 3.41 美元開盤。安康力醫療有一個十二個月低點 2.60 美元,十二個月高點為 90.00 美元。股票的五十天簡單移動平均線為 3.34 美元,其 200 天簡單移動平均線為 3.98 美元。
Institutional Trading of Incannex Healthcare
康康強醫療機構交易
Large investors have recently modified their holdings of the stock. Jane Street Group LLC acquired a new position in shares of Incannex Healthcare during the first quarter worth $378,000. FNY Investment Advisers LLC acquired a new position in shares of Incannex Healthcare during the third quarter worth $69,000. Finally, UBS Group AG acquired a new position in shares of Incannex Healthcare during the first quarter worth $25,000. Hedge funds and other institutional investors own 0.07% of the company's stock.
大型投資者最近修改了股票的持有量。簡街集團有限責任公司在第一季度收購了英康強醫療股份的新位置,價值 378,000 美元。FNY 投資顧問有限責任公司在第三季度收購了英康強醫療保健股份的新職位,價值 69,000 美元。最後,瑞銀集團股份有限公司在第一季度收購了盈康醫療股份的新頭寸,價值 25,000 美元。對沖基金和其他機構投資者擁有公司股票的 0.07%。
About Incannex Healthcare
關於康康強醫療
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies in Australia. It offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. The company also develops IHL-42X, which has completed Phase IIa clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis.
Incannex 醫療保健有限公司在澳大利亞從事藥用大麻素和迷幻藥物產品和療法的研究,開發和銷售。它提供了 ApiRX-1801,一種超純四氫大麻酚;APIRX-1802,一種超純中央商務區;以及一種超純大麻素 ApiRX-1803。公司還研發 IHL-42X,完成阻塞性睡眠呼吸暫停的 IIa 期臨床試驗;正在進行 IIa 期臨床試驗的全身焦慮症;MedCheg Dronabinol,已完成化療中噁心嘔吐的 Ia 期臨床試驗;CanChew Plus 已完成腸易激綜合徵 IIIa 期臨床試驗;APX-16Ia 臨床試驗已完成。白癜風;已完成 IIa 期牛皮癬臨床試驗的 APIRX-1602;以及已完成 IIIA 期臨床試驗的 APIRX-1603特應性皮炎的臨床試驗。
Featured Articles
特色文章
- Get a free copy of the StockNews.com research report on Incannex Healthcare (IXHL)
- Is Seagate Technology Signaling the End of its Normalization?
- eHealth Stock Rises from the Ashes. Time to Get In?
- Can Yext A.I. Search Platform Drive Growth in 2023?
- Cassava Sciences Stock Undervalued with Its $124 Price Target?
- Constellation Brands: Are Consumers Trading Down for Rail Drinks?
- 免費獲取有關英康強醫療的研究報告
- 希捷技術是否表示其正常化的結束?
- 醫健通股票從灰燼中升起。是時候進去了嗎?
- Yext 人工智能搜尋平台能在 2023 年推動增長嗎?
- 木薯科學股票被低估,其 124 美元的目標價格?
- 星座品牌:消費者是否會因鐵路飲料而下跌?
Receive News & Ratings for Incannex Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incannex Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
接收英康強醫療日報的最新消息和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件通訊接收有關 Incannex 醫療保健及相關公司的最新新聞和分析師評級的簡要每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧